Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

priority access

- PMLiVE

AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

AI in market access: silver bullet or spanner in the works?

By Emily Morton-West

Amiculum

- PMLiVE

What is willingness to pay? – Comparing price testing methodologies

Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

Petauri Evidence

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 15,000 people in the US

- PMLiVE

Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

The drug is already approved for certain cases of advanced or metastatic breast cancer

- PMLiVE

J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study

Alterations in EGFR are among the most common driver mutations in NSCLC patients

- PMLiVE

AstraZeneca shares ‘unprecedented’ survival results for Imfinzi/Imjudo regimen in liver cancer

Almost 900,000 new cases of liver cancer are diagnosed globally every year

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.

Petauri Evidence

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links